A 44-year-old married mother of three and a man half her age and just freshly engaged checked into UAB Hospital on Good ...
Despite a 10-year age gap and geographical separation, Sajarn and Codey Stow have retained a close bond since childhood. That ...
Povetacicept, a dual BAFF/APRIL inhibitor, significantly lowered proteinuria in patients with immunoglobulin A nephropathy ...
Immunoglobulin A (IgA) nephropathy is an autoimmune disease characterized by the deposition of circulating IgA-containing ...
Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced details for the next installment of their R&D Spotlight ...
Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today ...
Novartis (SWX:NOVN) reported final two year Phase III results for Fabhalta in IgA nephropathy. Data showed significant long ...
Idiopathic Membranous Nephropathy Market Is Predicted To Reach USD 1 Billion By 2036 Due To Rising Therapeutic Options ...
Learn more about whether Relay Therapeutics, Inc. or Travere Therapeutics, Inc. is a better investment based on AAII's A+ ...
The phase 2 ASSIST trial showed that atrasentan has an additional antiproteinuric effect -- approximately 25% -- over 12 weeks in patients with earlier-stage IgA nephropathy already receiving ...
Iptacopan is a complement factor B inhibitor targeting the overactive alternative complement pathway in IgA nephropathy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results